Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection

ACS Medicinal Chemistry Letters

Volumn 2, Issue 2, 2011, Pages 130-135

  Chang, Wonsuk ^a   Bao, Donghui ^a   Chun, Byoung Kwon ^a   Naduthambi, Devan ^a   Nagarathnam, Dhanapalan ^a   Rachakonda, Suguna ^a   Reddy, P Ganapati ^a   Ross, Bruce S ^a   Zhang, Hai Ren ^a   Bansal, Shalini ^a   Espiritu, Christine L ^a   Keilman, Meg ^a   Lam, Angela M ^a   Niu, Congrong ^a   Steuer, Holly Micolochick ^a   Furman, Phillip A ^a   Otto, Michael J ^a   Sofia, Michael J ^a  

^a PHARMASSET INC   (United States)

Author keywords

antivirals; hepatitis C virus; NS5B polymerase; nucleoside; phosphoramidate; prodrug; PSI 353661; triphosphate

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLGUANOSINE MONOPHOSPHATE; ANTIVIRUS AGENT; GUANOSINE DERIVATIVE; PHOSPHATE; PSI 353661; PURINE NUCLEOTIDE; TRIPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; HEPATITIS C; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; REPLICON; WILD TYPE;

HEPATITIS C VIRUS;

EID: 79951544544     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100209f     Document Type: Article

References (30)

1. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29 (S1) 74-81
2. Zeuzem, S.; Berg, T.; Moeller, B.; Hinrichsen, H.; Mauss, S.; Wedemeyer, H.; Sarrazin, C.; Hueppe, D.; Zehnter, E.; Manns, M. P. Expert opinion on the treatment of patients with chronic hepatitis C J. Viral Hepatitis 2009, 16, 75-90
3. Neukam, K.; Macias, J.; Mira, J. A.; Pineda, J. A. A review of current anti-HCV treatment regimens and possible future strategies Expert Opin. Pharmacother. 2009, 10, 417-433
4. Schinazi, R. F.; Bassit, L.; Gavegnano, C. HCV drug discovery aimed at viral eradication J. Viral Hepatitis 2010, 17, 77-90
5. Furman, P. A.; Lam, A. M.; Murakami, E. Nucleoside analogue inhibitors of hepatitis C viral replication: recent advances, challenges and trends Future Med. Chem. 2009, 1, 1429-1452
6. Carroll, S. S.; La Femina, R. L. Nucleoside analogue inhibitors of hepatitis C viral replication. In Antiviral Research; La Femina, R. L., Ed.; American Society for Microbiology: Washington, DC, 2009; pp 153 - 166.
7. Stuyver, L. J.; McBrayer, T. R.; Tharnish, P. M.; Clark, J. L.; Hollecher, L.; Lostia, S.; Nachman, T.; Grier, J.; Bennett, M. A.; Xie, M.-Y.; Schinazi, R. F.; Morrey, J. D.; Julander, J. L.; Furman, P. A.; Otto, M. J. Inhibition of hepatitis C replicon RNA synthesis by β- d -2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication Antiviral Chem. Chemother. 2006, 17, 79-87
8. Murakami, E.; Niu, C.; Bao, H.; Steuer, H. M.; Whitaker, T.; Nachman, T.; Sofia, M. A.; Wang, P.; Otto, M. J.; Furman, P. A. The mechanism of action of β- d -2′-deoxy-2′-fluoro-2′- C -methylcytidine involves a second metabolic pathway leading to β- d -2′-deoxy-2′-fluoro- 2′- C -methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase Antimicrob. Agents Chemother. 2008, 52, 458-464 (Pubitemid 351170814)
9. Le Pogam, S.; Kang, H.; Seshaadri, A.; Kosaka, A.; Hu, S.; Ewing, A.; Yan, J.-M.; Beard, A.; Symons, J.; Cammack, N.; Ńjera, I. No evidence of R7128 drug resistance after up to 4 weeks treatment of GT 1, 2 and 3 hepatitis C virus infected individuals. 44th Annual Meeting of the European Association for the Study of the Liver; Copenhagen, Denmark, April, 2009; Abstr. No. 839.
10. Clark, J. L.; Hollecker, L.; Mason, J. C.; Stuyver, L. J.; Tharnish, P. M.; Lostia, S.; McBrayer, T. R.; Schinazi, R. F.; Watanabe, K. A.; Otto, M. J.; Furman, P. A.; Stec, W. J.; Patterson, S. E.; Pankiewicz, K. W. Design, synthesis, and antiviral activity of 2′-deoxy-2′-fluoro-2′-C- methyl-cytidine, a potent inhibitor of hepatitis C virus replication J. Med. Chem. 2005, 48, 5504-5508 (Pubitemid 41209247)
11. Clark, J. L.; Mason, J. C.; Hollecker, L.; Stuyver, L. J.; Tharnish, P. M.; McBrayer, T. R.; Otto, M. J.; Furman, P. A.; Schinazi, R. F.; Watanabe, K. A. Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′- C -methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication Bioorg. Med. Chem. Lett. 2006, 16, 1712-1715 (Pubitemid 43197551)
12. Wang, P.; Sofia, M. J.; Chun, B.-K.; Du, J.; Rachakonda, S.; Steuer, H. M.; Murakami, E.; Bao, H.; Nagarathnam, D.; Otto, M. J.; Furman, P. A. d -2′-Deoxy-2′-fluoro-2′- C -methyl-ribofuranosyl nucleosides: Effect of base modifications on antihepatitis C virus activity. 238th ACS National Meeting, Washington, DC, August, 2009; MEDI 100.
13. Sofia, M. J.; Bao, D.; Chang, W.; Du, J.; Nagarathnam, D.; Rachakonda, S.; Reddy, P. G.; Ross, B. S.; Wang, P.; Zhang, H.-R.; Bansal, S.; Espiritu, C.; Keilman, M.; Lam, A. M.; Micolochick Steuer, H. M.; Niu, C.; Otto, M. J.; Furman, P. A. Discovery of a β- d -2′-deoxy-2′-fluoro-2′- β- C -methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J. Med. Chem. 2010, 53, 7202-7218
14. Oeberg, Bo. Rational design of polymerase inhibitors as antiviral drugs Antiviral Res. 2006, 71, 90-95
15. Hecker, S. J.; Erion, M. D. Prodrugs of phosphates and phosphonates J. Med. Chem. 2008, 51, 2328-2345 (Pubitemid 351628494)
16. Mehellou, Y.; Balzarini, J.; McGuigan, C. Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells ChemMedChem 2009, 4, 1779-1791
17. McGuigan, C.; Madela, K.; Aljarah, M.; Gilles, A.; Brancale, A.; Zonta, N.; Chamberlain, S.; Vernachio, J.; Hutchins, J.; Hall, A.; Ames, B.; Gorovits, E.; Ganguly, B.; Kolykhalov, A.; Wang, J.; Muhammad, J.; Patti, J. M.; Henson, G. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus Bioorg. Med. Chem. Lett. 2010, 20, 4850-4854
18. McGuigan, C.; Gilles, A.; Madela, K.; Aljarah, M.; Holl, S.; Jones, S.; Vernachio, J.; Hutchins, J.; Ames, B.; Bryant, K. D.; Gorovits, E.; Ganguly, B.; Hunley, D.; Hall, A.; Kolykhalov, A.; Liu, Y.; Muhammad, J.; Raja, N.; Walters, R.; Wang, J.; Chamberlain, S.; Henson, G. Phosphoramidate ProTides of 2′-C-methylguanosine as highly potent inhibitors of hepatitis C virus. study of their in vitro and in vivo properties J. Med. Chem. 2010, 53, 4949-4957
19. Wang, P.; Chun, B.-K.; Rachakonda, S.; Du, J.; Khan, N.; Shi, J.; Stec, W.; Cleary, D.; Ross, B. S.; Sofia, M. J. An efficient and diastereoselective synthesis of PSI-6130: a clinically efficacious inhibitor of HCV NS5B polymerase J. Org. Chem. 2009, 74, 6819-6824
20. The improved synthesis of the intermediate 5 will be published elsewhere.
21. McGuigan, C.; Hassan-Abdallah, A.; Srinivasan, S.; Wang, Y.; Siddiqui, A.; Daluge, S. M.; Gudmundsson, K. S.; Zhou, H.; McLean, E. W.; Peckham, J. P.; Burnette, T. C.; Marr, H.; Hazen, R.; Condreay, L. D.; Johnson, L.; Balzarini, J. Application of phosphoramidate ProTide technology significantly improves the antiviral potency of carbocyclic adenosine derivatives J. Med. Chem. 2006, 49, 7215-7226 (Pubitemid 44886007)
22. In addition to l -alanine, other amino acid derivatives were also prepared and studied (no data shown). However, the phosphoramidates of l -alanine were strongly preferred to the others in terms of anti-HCV potency in vitro.
23. For previously reported 6-modified guanine nucleotide analogues with anti-HCV activity, see: Gunic, E.; Girardet, J.-L.; Ramasamy, K.; Stoisavljevic-Petkov, V.; Chow, S.; Yeh, L.-T.; Hamatake, R. K.; Raney, A.; Hong, Z. Cyclic monophosphate prodrugs of base-modified 2′- C -methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication Bioorg. Med. Chem. Lett. 2007, 17, 2452-2455 (Pubitemid 46507791)
24. Lambe, C. U.; Averett, D. R.; Paff, M. T.; Reardon, J. E.; Wilson, J. G.; Krenitsky, T. A. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies Cancer Res. 1995, 55, 3352-3356
25. 50 > 100 μM), indicating the represented compounds are double prodrugs.
26. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 2010, 138, 447-462
27. Hocek, M.; Naus, P.; Pohl, R.; Votruba, I.; Furman, P. A.; Tharnish, P. M.; Otto, M. J. Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides J. Med. Chem. 2005, 48, 5869-5873 (Pubitemid 41298356)
28. Fleischer, R.; Boxwell, D.; Sherman, K. E. Nucleoside analogues and mitochondrial toxicity Clin. Infect. Dis. 2004, 38, e79-80
29. Ma, H.; Jiang, W.-R.; Robledo, N.; Leveque, V.; Ali, S.; Lara-Jaime, T.; Masjedizadeh, M.; Smith, D. B.; Cammack, N.; Klumpp, K.; Symons, J. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor β- d -2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species J. Biol. Chem. 2007, 282, 29812-29820 (Pubitemid 350035263)
30. When compound 23 was prepared by the method described in the Supporting Information. The ratio varies depending on the reaction conditions. Selective synthetic preparation of 23b will be reported elsewhere in the near future.